Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256409903> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4256409903 endingPage "1101" @default.
- W4256409903 startingPage "1100" @default.
- W4256409903 abstract "We read with interest the recent article by Weiser et al.1 They conducted a trial in patients with acute lymphocytic leukemia who were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) to delineate the impact of hyperglycemia on patient outcome. Hyperglycemia was found to occur in 37% of the patients. The patients who experienced hyperglycemia were found to have a shorter duration of complete remission compared with those patients without hyperglycemia. Patients with hyperglycemia also were found to have a shorter median overall survival, and they were more likely to develop sepsis and complicated infections. Weiser et al. also found hyperglycemia to be an independent risk factor for early disease recurrence and mortality on Cox regression analysis. However, we have a comment on the study. Corticosteroids are widely employed in the treatment of patients with cancer, especially those with lymphoid malignancies. Therefore, hyperglycemia is not an uncommon clinical occurrence during chemotherapy, as in the study by Weiser et al.1 In the case of hyperglycemia, the dose of corticosteroid usually is reduced or withdrawn from the treatment. The role of the relative dose intensity of the drugs used in the treatment was not discussed in the study by Weiser et al.1 Is hyperglycemia an independent risk factor based on the relative dose intensity of the drugs used in the treatment? Is there any difference with regard to the relative dose intensity between the patients with hyperglycemia and those without hyperglycemia, although the toxicity was not found to be different in hyperglycemic patients compared with those who were normoglycemic (most likely an indirect indicator of relative dose intensity)? The relative dose intensity should be included in analyses. Therefore, it is difficult to state with certainty that hyperglycemia is an independent risk factor in patients with acute lymphoblastic leukemia without incorporating the relative dose intensity in the analysis." @default.
- W4256409903 created "2022-05-12" @default.
- W4256409903 creator A5023398993 @default.
- W4256409903 creator A5033348156 @default.
- W4256409903 creator A5033798750 @default.
- W4256409903 creator A5090666502 @default.
- W4256409903 date "2004-08-18" @default.
- W4256409903 modified "2023-09-27" @default.
- W4256409903 title "Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen" @default.
- W4256409903 doi "https://doi.org/10.1002/cncr.20461" @default.
- W4256409903 hasPublicationYear "2004" @default.
- W4256409903 type Work @default.
- W4256409903 citedByCount "4" @default.
- W4256409903 countsByYear W42564099032018 @default.
- W4256409903 countsByYear W42564099032019 @default.
- W4256409903 crossrefType "journal-article" @default.
- W4256409903 hasAuthorship W4256409903A5023398993 @default.
- W4256409903 hasAuthorship W4256409903A5033348156 @default.
- W4256409903 hasAuthorship W4256409903A5033798750 @default.
- W4256409903 hasAuthorship W4256409903A5090666502 @default.
- W4256409903 hasBestOaLocation W42564099031 @default.
- W4256409903 hasConcept C126322002 @default.
- W4256409903 hasConcept C143998085 @default.
- W4256409903 hasConcept C2776694085 @default.
- W4256409903 hasConcept C2776755627 @default.
- W4256409903 hasConcept C2778041864 @default.
- W4256409903 hasConcept C2778461978 @default.
- W4256409903 hasConcept C2779429289 @default.
- W4256409903 hasConcept C2780401358 @default.
- W4256409903 hasConcept C2781059491 @default.
- W4256409903 hasConcept C2781107101 @default.
- W4256409903 hasConcept C2781413609 @default.
- W4256409903 hasConcept C2909962599 @default.
- W4256409903 hasConcept C71924100 @default.
- W4256409903 hasConcept C90924648 @default.
- W4256409903 hasConceptScore W4256409903C126322002 @default.
- W4256409903 hasConceptScore W4256409903C143998085 @default.
- W4256409903 hasConceptScore W4256409903C2776694085 @default.
- W4256409903 hasConceptScore W4256409903C2776755627 @default.
- W4256409903 hasConceptScore W4256409903C2778041864 @default.
- W4256409903 hasConceptScore W4256409903C2778461978 @default.
- W4256409903 hasConceptScore W4256409903C2779429289 @default.
- W4256409903 hasConceptScore W4256409903C2780401358 @default.
- W4256409903 hasConceptScore W4256409903C2781059491 @default.
- W4256409903 hasConceptScore W4256409903C2781107101 @default.
- W4256409903 hasConceptScore W4256409903C2781413609 @default.
- W4256409903 hasConceptScore W4256409903C2909962599 @default.
- W4256409903 hasConceptScore W4256409903C71924100 @default.
- W4256409903 hasConceptScore W4256409903C90924648 @default.
- W4256409903 hasIssue "5" @default.
- W4256409903 hasLocation W42564099031 @default.
- W4256409903 hasOpenAccess W4256409903 @default.
- W4256409903 hasPrimaryLocation W42564099031 @default.
- W4256409903 hasRelatedWork W1971347970 @default.
- W4256409903 hasRelatedWork W2020020572 @default.
- W4256409903 hasRelatedWork W2071798333 @default.
- W4256409903 hasRelatedWork W2128253927 @default.
- W4256409903 hasRelatedWork W2342164759 @default.
- W4256409903 hasRelatedWork W2383302662 @default.
- W4256409903 hasRelatedWork W2385309123 @default.
- W4256409903 hasRelatedWork W2409484189 @default.
- W4256409903 hasRelatedWork W310485701 @default.
- W4256409903 hasRelatedWork W4256409903 @default.
- W4256409903 hasVolume "101" @default.
- W4256409903 isParatext "false" @default.
- W4256409903 isRetracted "false" @default.
- W4256409903 workType "article" @default.